CJC-1295 raised GH 2- to 10-fold; synergy studies used other peptides

How are CJC-1295 and ipamorelin supposed to work together?

CJC-1295 and ipamorelin trigger the same pituitary growth hormone (GH) pulse through two different receptors. GH secretion is normally under dual control. GHRH (growth hormone-releasing hormone) binds its own receptor on pituitary somatotroph cells and stimulates release. Ghrelin and its synthetic mimics bind a separate receptor, the ghrelin receptor, and also stimulate release, largely independent of the GHRH pathway.

CJC-1295 is a GHRH analog designed to act on the GHRH receptor. Ipamorelin belongs to a different drug class: it is a selective growth hormone secretagogue that acts on the ghrelin receptor, GHS-R1a ^[16]⁠^[17]. Ipamorelin was developed and characterized as a selective ghrelin-receptor agonist, distinguished pharmacologically from GHRH-receptor compounds with receptor-specific antagonists in animal models ^[14]. Rat studies using autoradiography and surgical resection found that a meaningful portion of this drug class's GH-releasing effect depends on gastrointestinal tissue, where endogenous ghrelin is made, which reinforces that these compounds work through a route biologically distinct from GHRH ^[12].

Two molecules acting on two receptors that converge on one event, a GH pulse, is a textbook setup for additive or synergistic effects. Reviews of the peptide landscape for orthopedic and sports medicine consistently classify CJC-1295 and ipamorelin together as "growth hormone secretagogues" because of that shared endpoint through different receptors ^[16]. The receptor-level distinction is real pharmacology, not marketing spin.

The reasoning fails at the next step: the assumption that stimulating both receptors with CJC-1295 and ipamorelin in a person produces a larger, cleaner, or more predictable pulse than either alone. That claim is testable, and no human study has tested it.

Do GHRH analogs and ghrelin-receptor agonists raise GH more together?

Yes: GHRH-class and GHS-class peptides given together produce a bigger acute GH response than either alone, replicated across several peptide pairs in humans ^[2]⁠^[3]⁠^[4]⁠^[5]⁠^[8]. When ghrelin and GHRH were given together to healthy volunteers, the combined GH response exceeded either agent given by itself ^[2]. GHRH paired with GHRP-6 showed the same pattern in normal subjects ^[7].

The strongest direct human evidence for the synergy comes from GHRP-2, an older ghrelin-mimetic peptide, not ipamorelin. In normal men and women given GHRP-2, GHRH, or both, chronic administration converted an additive GH response into a synergistic one, and the pattern of synergy differed depending on whether GHRP-2 or GHRH was given first ^[8]. The relationship shifted over days with how long and how often the secretagogue was given, which makes it real human evidence that the synergy depends on dose and duration ^[8]. It says nothing about CJC-1295 or ipamorelin.

The effect holds in settings as different as healthy volunteers ^[2], critically ill adults given continuous infusions ^[3]⁠^[4]⁠^[5], and children undergoing diagnostic testing ^[7]. In prolonged critical illness, where GH secretion is severely blunted, GHRP-2 alone and GHRH plus GHRP-2 together restored pulsatile coordination between GH, TSH, and prolactin ^[3]⁠^[4]⁠^[5]. Those infusion studies show how far the mechanism has been probed, in patients nothing like a healthy adult chasing body composition change.

The synergy depends on an intact hypothalamic-pituitary connection. In children with a severed pituitary stalk, GHRH plus GHRP-6 produced no meaningful GH response at all, so the effect is not a purely pituitary-level trick and not "more receptor, more hormone" regardless of a person's underlying axis ^[7].

Animal data extend the concept. In GHRH-knockout mice, a GHRH analog combined with a GHRP produced greater body length and weight gain than the GHRH analog alone, and the mice needed the combination to mount any acute GH response when GHRH signaling was absent ^[13]. That mouse model used different molecules, JI-38 and GHRP-2, and mouse growth is not a stand-in for human GH pulse amplitude, let alone muscle or fat.

Has any human study tested CJC-1295 and ipamorelin together?

No human study has combined CJC-1295 with ipamorelin, in either the DAC or non-DAC form, at any dose or duration. Ipamorelin acts on the same receptor class as ghrelin, hexarelin, and GHRP-2, but it is a distinct molecule with its own binding and clearance profile, and none of the combination studies used it. The evidence on ipamorelin by itself is a separate question.

The popular protocol holds that CJC-1295 plus ipamorelin, at 100 to 200 mcg each injected nightly, produces the same magnitude of GH effect and translates into fat loss, lean mass, better sleep, or faster recovery. No study tests that claim, and the dosing figures do not trace to any study. The closest data are single-agent CJC-1295 pharmacology ^[1]⁠^[6] and combination data using other GHS-class peptides ^[2]⁠^[3]⁠^[4]⁠^[5]⁠^[7]⁠^[8].

Extrapolating from those studies to the stacked protocol requires two unverified assumptions: that ipamorelin behaves like the tested GHS peptides when combined with a GHRH analog, and that a nightly chronic regimen behaves like the single-dose or short-infusion designs that generated the synergy data.

A 2026 review of peptide use in recreational and professional sport and bodybuilding names both ipamorelin and CJC-1295 and makes the gap explicit: most published evidence examines therapeutic, controlled-dose regimens, not the combined or supraphysiological protocols used in bodybuilding and recreational settings ^[11]. Bodybuilders and recreational users are the people reading the vendor pages that quote a specific multiplier.

Where do the "3 to 5x" and "10x" GH figures come from?

The "3 to 5x" and "10x" figures for CJC-1295 plus ipamorelin trace to no study. Clinic and vendor pages claim the combination produces GH pulses three to five times baseline, versus roughly one and a half to two times for either peptide alone. A competing figure on the same category of pages claims up to ten times baseline. Neither number comes with a sample size, a dosing protocol, or a stated outcome measure.

The two figures cannot both describe the same phenomenon, a clue that neither was measured. When the parties selling a product present two contradictory precise statistics as established fact, both are extrapolations dressed up as data. The only multiplier in the cited studies belongs to CJC-1295 alone: a 2- to 10-fold rise in mean GH, depending on dose, after a single injection ^[1].

Precision is not sourcing. A figure like "3 to 5x" reads as more credible than a vague claim, and once one page states it with confidence, the next page copies it, so the number gains the look of settled science through repetition instead of measurement. The pattern is familiar from peptide and supplement marketing, and the sport and bodybuilding review notes that clinical evidence for combined bodybuilding-style protocols is limited even as their popularity grows ^[11].

Injection timing, dosing frequency, and the "response curves" published alongside these multipliers inherit the same problem. Pairing an unsourced number with a specific milligram dose and a time of day does not make it more trustworthy, and no trial in the current literature generated a "combined GH release" curve for this stack.

What does CJC-1295 do on its own?

A single CJC-1295 injection raised mean GH 2- to 10-fold, depending on dose, for six or more days in a randomized, placebo-controlled trial ^[1]. CJC-1295 is a long-acting GHRH analog that binds circulating albumin, which extends its half-life to 5.8 to 8.1 days. IGF-1 rose 1.5- to 3-fold and stayed raised for 9 to 11 days ^[1].

Those figures describe the DAC form, the version built for sustained exposure. They are single-agent results, with nothing stacked on top.

Does CJC-1295 with DAC flatten natural GH pulses?

CJC-1295 with DAC did not flatten GH pulses after a single dose. Pulse frequency and pulse magnitude stayed essentially unchanged, while the trough level between pulses rose about 7.5-fold, driving a 46% increase in mean GH and a 45% increase in IGF-1 ^[6]. The long-acting analog raises the floor the pulses sit on instead of eliminating pulsatility.

The question matters because GH pulsatility is thought to shape downstream GH signaling. The finding complicates the common claim that pairing a GHS with the DAC form "fights" pulsatility: in the trial, pulsatility survived, at least acutely and at the doses tested.

Is CJC-1295 the same product as CJC-1295 with DAC?

CJC-1295 and CJC-1295 with DAC are different products, though they are sometimes sold and described interchangeably. The DAC version is modified to extend how long the compound stays active in circulation, and the two differ substantially in duration of action. The 5.8 to 8.1 day half-life belongs to the DAC form ^[1]. The CJC-1295 trials report no equivalent pharmacokinetics for the short-acting, non-DAC version, sometimes called Mod GRF 1-29, so treating the two forms as interchangeable is an assumption the DAC data cannot settle.

A dosing protocol that does not say which version it means is not precise enough to evaluate, whatever multiplier comes attached. Product identity is a documented concern: the unregulated supply chain for these peptides has been flagged for mislabeling and inconsistent product quality ^[11]. Separate analyses cover what CJC-1295 with DAC does and does not show and the evidence on CJC-1295 without DAC.

Does a GH stimulation test predict what a nightly stack does?

A GHRH-plus-GHS stimulation test is a single-session diagnostic tool, not a model of weeks of nightly injections. Researchers developed combined stimulation to unmask how much GH-secreting capacity the pituitary retains, in settings ranging from suspected adult GH deficiency to critical illness physiology ^[3]⁠^[4]⁠^[5]⁠^[7]. The test runs over a single session or a short infusion window, with blood drawn every 15 to 20 minutes, and the result is compared to a threshold.

Injecting two peptides together every night for weeks, and judging success by a mirror and a scale instead of a timed hormone assay, is a fundamentally different exercise. Chronic dosing data show that the additive-versus-synergistic relationship itself changes over days of repeated exposure, so a single-dose diagnostic result cannot be assumed to describe what happens after weeks of nightly injections ^[8].

Does more growth hormone mean more muscle or less fat?

More circulating GH does not reliably deliver the physical outcomes people want, even when pharmaceutical GH is given directly. Controlled human trials of GH administration in athletic populations found an increase in lean body mass, but strength and exercise capacity did not reliably improve, and lactate levels rose ^[10]. In healthy older adults, GH therapy has not demonstrated established efficacy as an anti-aging intervention; that use is not FDA-approved, and distributing GH for it is illegal in the United States ^[9].

Those trials used pharmaceutical-grade GH itself, not GH-releasing peptides, at doses different from anything used recreationally. They still address the question that comes before any synergy multiplier: whether more circulating GH translates into the outcome a person wants. Even at the most rigorously studied end of this field, the answer is often no, or not clearly. Growth hormone's effects on body composition and strength are analyzed separately.

What is still unknown about CJC-1295 and ipamorelin?

For CJC-1295 plus ipamorelin, the unknowns are the core questions a decision depends on, not minor gaps at the edges:

• Dose and timing. No published human dose-response data exist for CJC-1295 plus ipamorelin co-administration. No one has established what dose or timing maximizes GH release from this combination in people, as opposed to in a mouse model of steroid-induced muscle wasting ^[15].
• Outcomes. No human trial measures whether the combination produces a different IGF-1 trajectory, body composition change, or side-effect profile than either agent alone. None of the cited studies measures fat mass, lean mass, sleep stages, injury recovery, or joint or skin outcomes for this pairing, or for any GHRH-plus-GHS combination.
• Safety. No human safety data exist for the combination, and human safety data for these compounds as a class remain limited ^[17].

None of this shows the mechanism is wrong, or rules out that a GHRH analog combined with a ghrelin-receptor agonist does what the theory predicts. The theory has not been tested where it counts. The receptor-level synergy is real and well documented across several GHRH-plus-GHS peptide pairs in careful human studies, while the stack, dose, ratio, and downstream promise sold under the CJC-1295-plus-ipamorelin name is an inference built on that literature, not a finding from it.

For someone already handling the fundamentals of sleep, training load, and protein intake, the stack's added value over either peptide alone, if any exists, has not been measured in any human trial.